Human leukocyte antigen

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious Diseases, Health Technology, Gen-Probe, Polymerase, NGS, Coagulation, Hepatitis, Fungal infection, Medicine, Infection, NAT, Molecular diagnostics, Geography, Urine, Roche, IVD, TB, Respiratory disease, Developed country, Gene, Human leukocyte antigen, Cancer, Prognosis, Single-nucleotide polymorphism, Risk, Polymerase chain reaction, HLA, Safety, COVID-19, Massive parallel sequencing, Immunoassay, Physician, HIV, BD (company), HPV, DSM-IV codes, PCR, AMR, Metabolism, Pharmacokinetics, Diagnosis, Blood, Growth, Vaccine

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

Hansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republic

Retrieved on: 
Monday, January 2, 2023
EMA, Quality of life, Mortality, Antibody, Priority, Medical research, Transplant, Patient, European, Nasdaq Stockholm, Dialysis, Kidney transplantation, Chronic kidney disease, Veni, vidi, vici, Medication package insert, Degenerative disease, Hospital, Kidney, Immunoglobulin G, Risk, Medicine, Safety, Kidney failure, ESRD, European Medicines Agency, State, Kidney disease, European Marketing Research Centre, Survival, Drug, Czech Republic, Human leukocyte antigen, Research, Cancer, DSA, Hansa, NIH, Health insurance, Dentistry, Pharmaceutical industry, Medical device, Agency

"We are very pleased to see that Idefirix® is now reimbursed in the Czech Republic for the treatment of highly sensitized kidney patients.

Key Points: 
  • "We are very pleased to see that Idefirix® is now reimbursed in the Czech Republic for the treatment of highly sensitized kidney patients.
  • These patients have a serious disease burden and unmet needs and this decision is a significant milestone for them", says Søren Tulstrup, President and CEO, Hansa Biopharma.
  • "For Hansa, this decision is well aligned with  our vision: A world where patients with rare immunologic diseases can lead long and healthy lives."
  • Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S.

Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

Retrieved on: 
Thursday, December 8, 2022
NIH, Immunoglobulin G, Kidney transplantation, Dialysis, ESRD, European Medicines Agency, Italian Medicines Agency, EMA, Patient, Cancer, DSA, Research, Hlas, Nasdaq Stockholm, Kidney disease, Degenerative disease, Medicine, Human leukocyte antigen, Veni, vidi, vici, Antibody, Survival, Kidney, Hansa, Medication package insert, State, Safety, Kidney failure, European, Chronic kidney disease, European Marketing Research Centre, Transplant, Risk, Dentistry, Pharmaceutical industry, Medical device, Agency

The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.

Key Points: 
  • The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.
  • By the time the body starts to synthesize new IgG, the patient will be receiving post transplant immunosuppressive therapy to reduce the risk of organ rejection.
  • Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

Retrieved on: 
Monday, September 12, 2022
Adult, Dialysis, Kidney Research UK, SMC, Safety, Healthcare Improvement Scotland, Priority, NHS Scotland, European Medicines Agency, Hansa, Risk, Kidney failure, ESRD, European, Hlas, Antibody, Product, Company, Population, Immunoglobulin G, Kidney disease, Nasdaq Stockholm, Survival, Patient, Program, Transplant, Cancer, Donation, Decision-making, Kidney transplantation, CEO, Chronic kidney disease, European Market Infrastructure Regulation, Quality of life, Degenerative disease, NASDAQ, Human leukocyte antigen, Research, Medicine, NICE, Hospital, State, Kidney, DSA, Veni, vidi, vici, NIH, EMA, Pharmaceutical industry, Dentistry, Medical device, Imlifidase, Agency

Kidney transplant candidates are classified as highly sensitized if they have a broad and intense range of pre-formed antibodies against almost all donororgans.

Key Points: 
  • Kidney transplant candidates are classified as highly sensitized if they have a broad and intense range of pre-formed antibodies against almost all donororgans.
  • It is fantastic to see that the SMC has followed the direction of England and Wales to offer certain highly sensitized patients the opportunity of a life-altering transplant.
  • "We are thrilled that the SMC has recommended Idefirixas the first licensed therapy for highly sensitized kidney patients in Scotland.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients

Retrieved on: 
Monday, July 11, 2022
Safety, Survival, Human leukocyte antigen, Kidney transplantation, World, Kidney, Priority, Quality of life, Veni, vidi, vici, Teaching hospital, Vall d'Hebron University Hospital, Medicine, Kidney disease, European Medicines Agency, Program, Hansa, Kidney failure, Vall, Company, Immunoglobulin G, State, Nasdaq Stockholm, EMA, Nephrology, Risk, Degenerative disease, ESRD, Dialysis, Cancer, Nasdaq, EudraCT, Transplant, DSA, Risk management, Patient, Research, European Market Infrastructure Regulation, Chronic kidney disease, Union, Antibody, NIH, Dentistry, Pharmaceutical industry, Medical device, European, Imlifidase, Agency

We can now happily report that our patient was the first to receive an Idefirix -enabled kidney transplant as part of this important study.

Key Points: 
  • We can now happily report that our patient was the first to receive an Idefirix -enabled kidney transplant as part of this important study.
  • This open-label Phase 3 study will enroll 50 highly sensitized adult kidney transplant patients with positive crossmatch against an available deceased donor to confirm the long-term efficacy and safety of Idefirix.
  • The PAES will enrol patients across multiple countries and centers in Europe and the study will include 50 highly sensitized and crossmatch positive patients to be treated with Idefirix.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

NICE recommends use of Hansa Biopharma's Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

Retrieved on: 
Thursday, June 16, 2022
Antibody, Hansa, Veni, vidi, vici, Mortality, Transplant, Royal commission, Safety, State, Priority, Decision-making, HLA, Kidney, MHRA, Health care, CEO, Survival, National Institute for Health and Care Excellence, European Medicines Agency, Company, Cancer, Chronic kidney disease, Research, Medication, Nasdaq Stockholm, Human leukocyte antigen, Degenerative disease, European, Kidney transplantation, Kidney failure, Program, Donation, ESRD, National Institute, Blood transfusion, Quality of life, Nasdaq, Immunoglobulin G, Dialysis, Adult, Kidney disease, Medicine, EMA, Patient, Database, NICE, Kidney Research UK, EU, European Commission, Risk, Pharmaceutical industry, Dentistry, Medical device, Agency

The recommendation marks an important milestone for patients in England, Wales and Northern Ireland, as appropriate specialized transplant centres will be able to use Idefirixto enable transplantation for highly sensitized patients, currently highly unlikely to receive a lifesaving compatible kidney transplant.

Key Points: 
  • The recommendation marks an important milestone for patients in England, Wales and Northern Ireland, as appropriate specialized transplant centres will be able to use Idefirixto enable transplantation for highly sensitized patients, currently highly unlikely to receive a lifesaving compatible kidney transplant.
  • "We welcome this decision, which will allow new opportunities for certain highly sensitized patients to qualify for a life-altering transplant, and gain freedom from dialysis.
  • Decision making around who has access to the treatment is key, and the lifespan of the transplanted kidneys will need to be carefully monitored."
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.

Versiti Launches HLA Loss of Heterozygosity Evaluation

Retrieved on: 
Tuesday, October 12, 2021
Escape Room, Transplant, Method, Physician, Multimedia, VP, LOH, Health, Immunotherapy, Cancer, Human leukocyte antigen, Hematology, Zygosity, Flow cytometry, Partnership, HLA, Patient, Research, Transfusion medicine, Medical device, Dentistry

MILWAUKEE, Oct. 12, 2021 /PRNewswire/ -- Versiti, Inc., one of the nation's leading blood health and research organizations, today announced a new test for detecting and characterizing genomic loss of heterozygosity (LOH) in the Human Leukocyte Antigen (HLA) region.

Key Points: 
  • MILWAUKEE, Oct. 12, 2021 /PRNewswire/ -- Versiti, Inc., one of the nation's leading blood health and research organizations, today announced a new test for detecting and characterizing genomic loss of heterozygosity (LOH) in the Human Leukocyte Antigen (HLA) region.
  • Groundbreaking test helps detect and characterize genomic loss of heterozygosity in the HLA region.
  • Under the direction of Jennifer Schiller Ph.D., D(ABHI), the Versiti Histocompatibility Lab has created a comprehensive evaluation to detect genomic loss of heterozygosity specifically for transplant patients.
  • "We expect that our HLA Loss of Heterozygosity evaluation test will provide valuable information to physicians, enabling them to make better-informed decisions during post-transplant disease relapse, potentially giving patients better outcomes," said Dr. Matthew Anderson, VP and medical director, Versiti Diagnostic Laboratories.

IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes

Retrieved on: 
Wednesday, July 21, 2021
Health, Other Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Gluten sensitivity, Diabetes, MHC Class II, Gastrointestinal tract disorders, Human leukocyte antigen, HLA-DQ8, HLA-DQ, DQ8

The single-blinded Phase 1b Multiple Ascending Dose (MAD) trial enrolled 30 T1D patients preselected for HLA-DQ8 between the ages of 18 and 45 into four groups.

Key Points: 
  • The single-blinded Phase 1b Multiple Ascending Dose (MAD) trial enrolled 30 T1D patients preselected for HLA-DQ8 between the ages of 18 and 45 into four groups.
  • Results of the Phase 1b study showed that IMT-002 was safe and well-tolerated.
  • IMT-002 completed a Phase 1a study in 2020 and has completed a Phase 1b study in T1D patients preselected for the HLA-DQ8 isoform.
  • The Company is building a broad HLA-targeted pipeline in autoimmune disorders including type 1 diabetes, celiac disease, and lupus.

BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Medical specialties, Immune system, Immunology, Single-pass transmembrane proteins, Cell signaling, T-cell receptor, T cell, Human leukocyte antigen, ImmTAC, MHC restriction

BASEL, Switzerland and TBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs).

Key Points: 
  • BASEL, Switzerland and TBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs).
  • For this reason, BioCopy has developed an innovative technology that enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes.
  • With this technology BioCopy is contributing a safety screening for novel TCR-based cancer cell therapies.
  • The goal of this collaboration is to enable the characterization of more than 5,000 different TCR-peptide-HLA interactions simultaneously.

IM Therapeutics Co-Founder and CMO Peter Gottlieb, M.D, to Present Advances in Genetically Targeted Therapies for Type 1 Diabetes at the 2021 ADA Scientific Sessions

Retrieved on: 
Thursday, June 24, 2021
Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Syndromes, Endocrine diseases, Human leukocyte antigen, Immune system, Transfusion medicine, Autoimmunity, Autoimmune disease, Sjögren syndrome

IM Therapeutics, Inc. announced today that Peter Gottlieb, M.D., Co-founder and Chief Medical Officer, will present at the American Diabetes Association (ADA) 81st Scientific Sessions, held June 25-29, 2021.

Key Points: 
  • IM Therapeutics, Inc. announced today that Peter Gottlieb, M.D., Co-founder and Chief Medical Officer, will present at the American Diabetes Association (ADA) 81st Scientific Sessions, held June 25-29, 2021.
  • IM Therapeutics is a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases.
  • Dr. Gottliebs talk, entitled Genetically Selected Patients for Targeted Immune Therapy, will take place during the Personalized Medicine for Immune Therapies in Type 1 Diabetes session on Sunday, June 27.
  • The Company is building a broad HLA-targeted pipeline in autoimmune disorders including type 1 diabetes, celiac disease, and lupus.